Related Experiment Videos
Dopamine suppresses thyroid-stimulating hormone secretion in neonatal hypothyroidism
F de Zegher1, G Van den Bershe, M Dumoulin
1Department of Pediatrics, University Hospital Gasthuisberg, University of Leuven, Belgium.
Acta Paediatrica (Oslo, Norway : 1992)
|February 1, 1995
Summary
Dopamine infusion, used in neonatal intensive care, can inhibit thyroid stimulating hormone (TSH) release. This may interfere with screening for neonatal hypothyroidism, potentially leading to misdiagnosis in newborns.
Area of Science:
- Neonatal Medicine
- Endocrinology
- Pharmacology
Background:
- Dopamine is a key therapy in neonatal intensive care, inhibiting thyroid stimulating hormone (TSH) release.
- Neonatal hypothyroidism screening relies on measuring serum TSH concentrations.
- Infants with congenital heart disease and hypothyroidism are at high risk for cardiocirculatory complications.
Observation:
- In an infant with congenital heart disease and hypothyroidism, dopamine withdrawal caused a rapid increase in serum TSH levels.
- TSH levels doubled within 40 minutes of discontinuing dopamine infusion.
- This observation suggests dopamine administration suppresses TSH secretion in neonates.
Findings:
- Dopamine infusion has an inhibitory effect on neonatal TSH hypersecretion.
- The use of dopamine therapy can mask or alter TSH levels in newborns.
- This effect poses a significant challenge for accurate neonatal hypothyroidism screening.
Implications:
- Dopamine therapy can be a diagnostic pitfall in screening for neonatal hypothyroidism.
- Clinical protocols may need adjustment to account for dopamine's effect on TSH levels.
- Accurate diagnosis of neonatal hypothyroidism is crucial for preventing long-term health issues.